白介素-2、顺铂及两药联合局部治疗恶性胸腔积液的汇集分析

汪睿; 史清明

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

白介素-2、顺铂及两药联合局部治疗恶性胸腔积液的汇集分析

汪睿 , 史清明

文章导航 > 蚌埠医学院学报 > 2013, 37 > 5: (565-568,571)

引用本文:

Citation:

白介素-2、顺铂及两药联合局部治疗恶性胸腔积液的汇集分析

汪睿,
史清明^,

1.
安徽省胸科医院肿瘤科, 安徽合肥 230022

作者简介: 汪睿(1977－ ),男,主治医师.

通讯作者: 史清明, shqm0324@163.com

基金项目:

A pooled analysis of intrapleural perfusion with interleukin-2 and /or cisplatin for malignant pleural effusion

WANG Rui,
SHI Qing-ming^,

1.
Department of Oncology, Anhui Chest Hospital, Hefei Anhui 230022, China

Corresponding author: SHI Qing-ming, shqm0324@163.com

摘要: 目的:探讨白介素-2(IL-2)、顺铂(DDP)或两药联合在胸腔局部使用治疗恶性胸腔积液(MPE)的临床运用价值。方法:对1993～2009年文献中关于MPE治疗3 778例患者疗效、不良反应的数据进行汇集分析,分为IL-2组1 499例,DDP组708例,IL-2+DDP组1 571例。再以随机研究,非合并其他治疗为筛选标准筛选出临床随机对照试验数据,IL-2组335例,DDP组513例,IL-2+DDP组460例。结果:IL-2组总有效率80.05%及IL-2+DDP组81.41%均高于DDP组58.05%;3组总体不良反应中发热、骨髓毒性、胸痛、消化道反应、肝功能损伤及肾功能损伤发生率差异均有统计学意义(P0.01)。IL-2+DDP组随机数据有效率84.13%、IL-2组77.01%均高于DDP组58.67%(P0.05);3组随机研究患者发热、骨髓毒性、胸痛、消化道反应、肝功能损伤及肾功能损伤发生率差异均有统计学意义(P0.01)。结论:IL-2对MPE有明显的疗效,晚期恶性肿瘤伴有MPE的患者,IL-2单药治疗在保证较好疗效的同时,具有相对较好的耐受性,可显著提高患者生活质量。
- 胸腔积液 /
- 白介素-2 /
- 顺铂
Abstract: Objective: To evaluate the clinical value of intrapleural perfusion of interleukin-2(IL-2),cisplatin(DDP) or the combined therapy for malignant pleural effusion(MPE) patient.Methods: A pooled analysis was taken which based on the data of efficacy and toxicity of treatments in 3 778 MPE patients from 1993 to 2009,1 499 patients were treated with IL-2 alone,708 patients were treated with cisplatin alone,and 1 571 patients were treated by the combined therapy.The clinic randomized control trail data were screened according to the standard of randomized study without other therapies.Three hundred thirty and five patients were in the IL-2 group,513 patients were in the DDP group and 460 patients were in the combined therapy group.Results: In non-randomized study,the effective rate in IL-2 group was 80.05%,the combined therapy group was 81.41%,which were higher than in DDP group with 58.05%.The adverse reaction rates including heating,bone marrow toxicity,chest pain,gastrointestinal reaction,hepatotoxic and nephrotoxicity had significant differences(P 0.01).In randomized study,the effective rate in IL-2 group was 77.01% and the combined therapy group was 84.13%,which were higher than in DDP group with 58.67%(P 0.05).The adverse reaction rates including heating,bone marrow toxicity,chest pain,gastrointestinal reaction,hepatotoxic and nephrotoxicity had significant differences(P 0.01) among 3 groups in randomized study.Conclusions: It has a good effective therapy with IL-2 alone and well tolerated for MPE patients,which could improve the quality of life.
- malignant pleural effusion /
- interleukin-2 /
- cisplatin

[2] Anderson SW,Lucey BC,Varghese JC,et al.Sixty-four multidetector row computed tomography in multitrauma patient imaging: early experience[J].Curr Probl Diagn Radiol,2006,35( 5):188-198.
[2]	孙燕.内科肿瘤学[M].北京: 人民卫生出版社,2001: 257.
[3] 孙燕,石远凯.临床肿瘤内科手册[M].北京: 人民卫生出版社,2008: 700.
[4] Neragi-Miandoab S.Malignant pleural effusion,current and evolving approaches for its diagnosis and management[J].Lung Cancer, 2006, 54( 1):1-9.
[5] 吴华家,张捷.白介素-2 治疗30 例肺癌MPE 的临床观察[J].临床肺科杂志,2005, 10( 3):279-280.
[6] Yasumoto K,Mivazaki K,Nagashina A,et al.Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interlukin-2 in patients with malignant pleurisy due to lung cancer[J].Cancer Res, 1987,47( 8):2184-2187.
[7] 李殿俊,张士安,林科,等.基因工程人白细胞介素22 治疗癌性胸腹水的2 期临床观察[J].中国生物制品学杂志,1995,8( Suppl):14.
[8] 徐嘉彰,朱莉贞,朱允中,等.基因工程人白细胞介素22 治疗MPE的疗效观察[J].中国生物制品学杂志, 1995,8( Suppl):16.
[9] 张天泽,徐光炜.肿瘤学[M].天津: 天津科学技术出版社,2005: 798-799.
[10] 田力,聂青,杨平.热疗加胸腔内生物化疗方法治疗恶性胸腔积液[J].长治医学院学报,2007,21( 1):25-26.
[11] 汪竹,童建东,袁昕,等.伊立替康联合DDP 治疗紫杉类失败的晚期胃癌[J].实用临床医药杂志,2008,12( 3):74-77.
[12] 王立伟,焦顺昌.MPE 的综合治疗新进展[J].中国肿瘤临床,2006, 33( 4):236.
[13] 游庆军,常建华,蒋锡初.射频消融联合紫杉醇DDP 方案治疗晚期肺癌疗效观察[J].实用临床医药杂志,2008,12( 1):76-77.
[14] Ishida A,Miyazawa T,Miyazu Y, et al.Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non-small cell lung cancer[J].Respirology, 2006,11( 1):90-97.
[15] 仇铁峰,钱巍.胸腔内注入DDP、丝裂霉素、联合白介素-Ⅱ治疗MPE 疗效比效[J].实用临床医药杂志,2007,11 ( 6 ):83-84.

[1]	张静 , 钟春生 , 李露 , 张伟 . 顺铂联合香菇多糖胸腔灌注治疗恶性胸腔积液临床观察. 蚌埠医学院学报, 2010, 35(3): 250-251.
[2]	禹莉 , 凌云志 . 顺铂对肝癌细胞株HepG2增殖和SATB1表达的影响. 蚌埠医学院学报, 2012, 36(8): 877-880.
[3]	苏凯 , 赵报 , 马莹晔 , 李慧 , 周帅 , 王晓敏 , 张俊杰 , 马士崟 . Vγ9Vδ2 T细胞联合顺铂增强对鼻咽癌细胞的杀伤作用. 蚌埠医学院学报, 2022, 47(11): 1479-1483. doi: 10.13898/j.cnki.issn.1000-2200.2022.11.001
[4]	季静 , 张晔 , 陆晓红 , 徐锋 , 詹惠英 . 顺铂通过增加HeLa人宫颈癌细胞中Nrf2入核促进细胞自噬和凋亡. 蚌埠医学院学报, 2023, 48(3): 301-305. doi: 10.13898/j.cnki.issn.1000-2200.2023.03.005
[5]	任立梅 , 陈付华 . 胸腔置管引流及注药治疗恶性胸腔积液的护理. 蚌埠医学院学报, 2007, 32(3): 355-356.
[6]	高华 , 王安潮 , 陈余清 , 徐凤珍 , 刘超 . 胸腔积液端粒酶活性检测及其临床意义. 蚌埠医学院学报, 2004, 29(3): 231-234.
[7]	孙桂清 , 彭霞林 , 蒋晓红 . 恶性胸腔积液患者中心静脉导管引流的护理. 蚌埠医学院学报, 2009, 34(6): 543-544.
[8]	戴素俊 , 施明美 , 胡江 , 夏峰 . 腺苷脱氨酶、C-反应蛋白与癌胚抗原检测对胸腔积液的诊断价值. 蚌埠医学院学报, 2006, 31(4): 422-423.
[9]	孙军 , 高忠和 , 刘华莎 , 周曦 , 张锋 , 杨玲 , 方陈 , 陈寒 , 韩忠朝 . ARROW中心静脉三通导管微创置入胸膜腔引流联合胸膜腔注入凝血酶治疗恶性胸腔积液. 蚌埠医学院学报, 2010, 35(10): 1009-1011.
[10]	孙丽芳 , 陈余清 , 赵成岭 , 李伟 , 李殿明 . 生存素基因联合细胞角蛋白19片段抗原及癌胚抗原检测对肺癌引起胸腔积液的诊断意义. 蚌埠医学院学报, 2010, 35(10): 993-995.
[11]	刘海涛 , 陈余清 , 李殿明 , 李伟 , 王效静 , 吴穷 , 孙耕耘 , 闵生萍 . 晚期非小细胞肺癌胸腔积液表皮生长因子受体突变检测对厄洛替尼疗效的预测价值. 蚌埠医学院学报, 2016, 41(11): 1422-1426,1430. doi: 10.13898/j.cnki.issn.1000-2200.2016.11.006
[12]	马朝燕 . 胸膜活检在渗出性胸腔积液中的诊断价值. 蚌埠医学院学报, 2016, 41(8): 1048-1049. doi: 10.13898/j.cnki.issn.1000-2200.2016.08.022
[13]	李骏 , 杨艳丽 , 耿英华 , 纪淑仪 . 以浆膜腔积液为首发症状的造血和淋巴组织肿瘤19例分析. 蚌埠医学院学报, 2007, 32(4): 417-418.
[14]	毕国斌 , 王子安 , 赵福友 , 王洪亚 . 闭式引流及香菇多糖腔内灌注治疗恶性胸腹腔积液临床观察. 蚌埠医学院学报, 2009, 34(4): 305-306.
[15]	蒋鹏程 , 周蓓蓓 , 董丽萍 , 周晨 . 放疗联合顺铂化疗治疗Ⅲ期子宫颈癌疗效分析. 蚌埠医学院学报, 2006, 31(6): 637-639.
[16]	王小芳 , 沈梅竹 , 汪济东 , 庞东生 . 简化水化方案预防顺铂肾毒性105例的护理经验. 蚌埠医学院学报, 2004, 29(2): 185-185.
[17]	金建华 , 王芳 , 陆文斌 , 赵宏祥 , 倪晓谦 . 多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察. 蚌埠医学院学报, 2005, 30(6): 513-515.
[18]	孙惠娟 , 秦凤展 , 郑荣生 , 汪子书 , 王洪亚 , 刘铁成 . 多西他赛联合顺铂治疗晚期乳腺癌临床观察. 蚌埠医学院学报, 2006, 31(5): 468-469.
[19]	夏晓阳 , 叶爱和 , 陈爱民 , 许静 . 低剂量氟尿嘧啶联合小剂量顺铂治疗晚期胃癌疗效观察. 蚌埠医学院学报, 2006, 31(5): 521-522.
[20]	夏晓阳 , 叶爱和 , 陈爱民 , 尤冬山 . 吉西他滨联合顺铂治疗晚期非小细胞肺癌42例观察. 蚌埠医学院学报, 2007, 32(5): 551-553.

点击查看大图

计量

文章访问数: 2563
HTML全文浏览量: 282
PDF下载量: 109
被引次数: 0

白介素-2、顺铂及两药联合局部治疗恶性胸腔积液的汇集分析

汪睿
史清明^,

通讯作者: 史清明, shqm0324@163.com

作者简介: 汪睿(1977－ ),男,主治医师.

1. 安徽省胸科医院肿瘤科, 安徽合肥 230022

收稿日期: 2012-08-29
网络出版日期: 2013-05-15

基金项目:

关键词:

胸腔积液 /
白介素-2 /
顺铂

摘要: 目的:探讨白介素-2(IL-2)、顺铂(DDP)或两药联合在胸腔局部使用治疗恶性胸腔积液(MPE)的临床运用价值。方法:对1993～2009年文献中关于MPE治疗3 778例患者疗效、不良反应的数据进行汇集分析,分为IL-2组1 499例,DDP组708例,IL-2+DDP组1 571例。再以随机研究,非合并其他治疗为筛选标准筛选出临床随机对照试验数据,IL-2组335例,DDP组513例,IL-2+DDP组460例。结果:IL-2组总有效率80.05%及IL-2+DDP组81.41%均高于DDP组58.05%;3组总体不良反应中发热、骨髓毒性、胸痛、消化道反应、肝功能损伤及肾功能损伤发生率差异均有统计学意义(P0.01)。IL-2+DDP组随机数据有效率84.13%、IL-2组77.01%均高于DDP组58.67%(P0.05);3组随机研究患者发热、骨髓毒性、胸痛、消化道反应、肝功能损伤及肾功能损伤发生率差异均有统计学意义(P0.01)。结论:IL-2对MPE有明显的疗效,晚期恶性肿瘤伴有MPE的患者,IL-2单药治疗在保证较好疗效的同时,具有相对较好的耐受性,可显著提高患者生活质量。

English Abstract

A pooled analysis of intrapleural perfusion with interleukin-2 and /or cisplatin for malignant pleural effusion

WANG Rui
SHI Qing-ming^,

Corresponding author: SHI Qing-ming, shqm0324@163.com

1. Department of Oncology, Anhui Chest Hospital, Hefei Anhui 230022, China

Received Date: 2012-08-29
Available Online: 2013-05-15

Abstract: Objective: To evaluate the clinical value of intrapleural perfusion of interleukin-2(IL-2),cisplatin(DDP) or the combined therapy for malignant pleural effusion(MPE) patient.Methods: A pooled analysis was taken which based on the data of efficacy and toxicity of treatments in 3 778 MPE patients from 1993 to 2009,1 499 patients were treated with IL-2 alone,708 patients were treated with cisplatin alone,and 1 571 patients were treated by the combined therapy.The clinic randomized control trail data were screened according to the standard of randomized study without other therapies.Three hundred thirty and five patients were in the IL-2 group,513 patients were in the DDP group and 460 patients were in the combined therapy group.Results: In non-randomized study,the effective rate in IL-2 group was 80.05%,the combined therapy group was 81.41%,which were higher than in DDP group with 58.05%.The adverse reaction rates including heating,bone marrow toxicity,chest pain,gastrointestinal reaction,hepatotoxic and nephrotoxicity had significant differences(P 0.01).In randomized study,the effective rate in IL-2 group was 77.01% and the combined therapy group was 84.13%,which were higher than in DDP group with 58.67%(P 0.05).The adverse reaction rates including heating,bone marrow toxicity,chest pain,gastrointestinal reaction,hepatotoxic and nephrotoxicity had significant differences(P 0.01) among 3 groups in randomized study.Conclusions: It has a good effective therapy with IL-2 alone and well tolerated for MPE patients,which could improve the quality of life.